This Snowflake Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• HC Wainwright & Co. analyst Emily Bodnar upgraded the rating for AnaptysBio, Inc. ANAB from Neutral to Buy and raised the price target from $22 to $38. AnaptysBio shares closed at $23.52 on Tuesday. See how other analysts view this stock.
• Barclays analyst David Anderson upgraded Cactus, Inc. WHD from Equal-Weight to Overweight and raised the price target from $51 to $54. Cactus shares closed at $44.11 on Tuesday. See how other analysts view this stock.
• HSBC analyst Cenk Orcan upgraded the rating for Embraer S.A. ERJ from Hold to Buy and raises the price target from $45 to $57. Embraer shares closed at $45.99 on Tuesday. See how other analysts view this stock.
• Citigroup analyst David Lebowitz upgraded Blueprint Medicines Corporation BPMC from Sell to Neutral and raised the price target from $83 to $129. Blueprint Medicines shares closed at $127.60 on Tuesday. See how other analysts view this stock.
• UBS analyst Karl Keirstead upgraded Snowflake Inc. SNOW from Neutral to Buy and raised the price target from $210 to $265. Snowflake shares closed at $209.18 on Tuesday. See how other analysts view this stock.

Considering buying SNOW stock? Here’s what analysts think:

Latest Startup Investment Opportunities:

Read This Next:

• Cramer: Should’ve Told Investors To ‘Pull The Trigger’ On Trade Desk, Can’t Believe ‘How Low’ Gentex Has Fallen

Photo via Shutterstock